Search Results

This research study includes two studies in one; a Phase 2 study and a Phase 3 study. The main goal of the Phase 2 study is to see if Brepocitinib is safe and if it works for adult participants who have active, moderate to severe lichen planopilaris (LPP). The main goal of the Phase 3 study is to see how well the treatment, Brepocitinib, works for those with LPP, in comparison to placebo (no active ingredient). Throughout the study, which lasts about 60 weeks, participants will complete questionnaires, have their LPP checked by the doctor, and undergo several procedures, including an EKG, a chest X‑ray, photographs, and blood tests.

Participants will be required to attend 13 in person visits. In addition, at week 4 participants will be required to stay for 1 hour after they take their study medicine to have their blood drawn.

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with atrial fibrillation and a recent brain hemorrhage to see which is better at preventing future strokes and death.

This study is for patients who have had a recent brain bleed (hemorrhagic stroke) within the past six months and also have a history of afib. Participants will be randomized to either aspirin OR apixaban. The assigned medication will be provided free of cost to participants for the duration of study participation. There will be up to 13 study visits over the course of 2-3 years. The first visit MUST be in person, but some follow up visits can be conducted via phone if necessary. Blood will be collected at the first visit only. All visits will involve filling out questionnaires, collecting vitals, and reviewing medications and medical history.

$650

This study is assessing the safety and tolerability of a new investigational treatment for glioma brain cancer. The treatment, Bilateral Hemispheric 5-ALA–Mediated Sonodynamic Therapy, and referred to as Porphyrin Metabolite Activation (PoMA™), combines a oral drug with targeted ultrasound therapy.

Once you sign consent, there will be a screening visit which may include a CT scan, blood tests, and study assessments/exams. Once screening results have been confirmed, you will receive your first 2 treatments 5-ALA-mediated sonodynamic therapy using the LIDU System before standard radiochemotherapy. After your radiochemotherapy and during adjuvant Temozolomide, you will continue the study treatment once every 30 days for up to 4 additional cycles. Your participation will last approximately 24 months including long-term follow up.